History

The Narrative Arc

Convatec is a turnaround story that has paid off — but the pay-off is being collected by a different management team than the one that built it. Karim Bitar arrived in 2019 to fix a business that had imploded after its 2016 IPO; six years and a 460 bps margin expansion later, he stepped down in August 2025 and died in October 2025. CFO Jonny Mason inherited a stronger company, a successful FISBE strategy, an InnovaMatrix reimbursement crisis, an FDA Warning Letter, the exit of cornerstone shareholder Novo Holdings, and the privilege of raising medium-term growth guidance from 5–7% to 6–8% under a re-branded "Accelerate" plan. The story today is sharper than at any point since the IPO — and also more concentrated on execution by a CEO who has been in the seat for under a year.

A 10-year arc in one timeline

Organic growth and margin: the FISBE proof points

Five consecutive years inside the 5–7% organic band (2021–2025), four consecutive years of margin expansion (+460 bps cumulatively), and double-digit EPS growth in 2024 and 2025. By any reasonable test, FISBE delivered.

What Management Emphasized — and Then Stopped Emphasizing

The vocabulary of the company has shifted in three distinct phases. Pre-2019 messaging is dominated by post-IPO damage control. 2019–2024 is dominated by FISBE pillars (Focus, Innovate, Simplify, Build, Execute). 2025–2026 introduces three new themes — acceleration, execution under stress, and quality remediation — while simplification and G&A reduction quietly recede as the primary story.

Three patterns matter:

• Simplification / G&A is being de-emphasized. G&A is now 6.8% of sales, already inside the originally stated 7% target; the cost story has done its work. Future margin expansion has to come from operating leverage and mix, not headcount cuts.
• Capacity / capex has surged. Growth capex more than doubled in 2025 (to $121M) and is guided to $135–165M in 2026 with a similar 2027 — a ~9% of sales total capex level. The narrative has shifted from "we don't need to invest" to "we have more demand than we can serve."
• Quality / FDA was barely mentioned through 2024 except as a generic principal risk; it is now top-of-mind after the February 2026 FDA Warning Letter to Unomedical and the CEO's blunt acknowledgement that complaint handling "is not good enough."

Risk Evolution

The principal-risk register has been re-ordered. Operational Resilience & Quality moved to position 1 in the FY25 ranking. Customer & Markets risk was elevated. Reimbursement, which lived inside Customer & Markets, has become the most scrutinized topic in the analyst community.

Newly visible risks in 2025: a US-facing FDA quality risk that was nominal until the Unomedical Warning Letter; a CMS competitive-bidding programme (DMEPOS CBP) that could remove 1–2% of group revenue from 2028; and the Section 232 tariff probe on medical device imports that creates a tail risk to the Nairobi Protocol (the carve-out Convatec is relying on).

Risks management has quietly de-emphasized: Brexit / EU MDR, which dominated risk discussion in 2019–2021 and is now largely silent; and the GLP-1 / insulin-pump cannibalization fear that briefly threatened the Infusion Care thesis in 2023. By 2025 the company is openly mocking the GLP-1 narrative — "everyone thought the Infusion Care business was in trouble. Far from it."

How They Handled Bad News

Three episodes test management's candour. The pattern across all three is consistent: Convatec acknowledges the issue plainly, quantifies the headwind early, and avoids surprise revisions. The execution wobble in 2025 was the softest-handled.

Guidance Track Record

Promises that mattered to valuation, not every modelling input. Convatec has met or beaten its medium-term targets twice and raised them twice.

The pattern: organic growth and margin landed inside the guided band. EPS came in above the double-digit promise (16% vs ≥10%). InnovaMatrix landed at the low end of the guided band as the CMS uncertainty bit harder than originally modelled. Capex overshot — but management front-loaded it deliberately and pre-announced the increase ($130–150M → $160–180M at the November 2025 trading update), which is the right way to break a guide upward.

Why 8/10: five consecutive years inside the organic-growth band; two upward revisions to the medium-term target; G&A target hit early; margin compounding on schedule. The deductions: the 2025 IMX guide was raised mid-year then walked back at year-end; the FDA letter is a quality-system failure that should not have happened in a medical-devices company with a "global quality" pillar; and the CEO transition introduces new-leadership uncertainty that a pure 10/10 score would not carry.

What the Story Is Now

Convatec today is a four-category chronic-care compounder with the strongest pipeline in its history (16 launches across Waves 1 and 2; Wave 3 emerging), structural volume tailwinds, ~80% recurring revenue, and a credible 6–8% growth / mid-20s margin / double-digit EPS algorithm. This is a much simpler thesis than at any point since the 2016 IPO. The reader should believe the algorithm.

What is de-risked:

• the strategic redirection (FISBE → Accelerate is an evolution, not a pivot)
• the cost story (G&A target met, automation in place)
• the IMX overhang (rebased, impaired, $20M baseline)
• the GLP-1 / Infusion Care fear (now driving capex shortage, not demand collapse)

What still looks stretched:

• the 6–8% organic guide leans on Wave 2 launches (ConvaNiox, ConvaFiber, ConvaVac, Natura Body, GC Air Pocket/Set) that are barely launched or launching imminently — execution risk is concentrated in the next 24 months
• ConvaNiox, the new-category bet, is being launched deliberately slowly to build evidence; sales remain immaterial in 2026 and the US de novo pathway is not yet started
• the FDA Warning Letter remediation is open-ended and Infusion Care is the highest-growth, most contract-underwritten category — a remediation slip would hit the part of the business where it hurts most
• the CMS DMEPOS CBP for ostomy and continence is still pending; 2028 is the first year of impact and management is assuming distributor consolidation will work in their favour
• Section 232 tariff probe on medical-device imports is a tail risk to the Nairobi Protocol carve-out

What to discount: the "we are now ready to accelerate" framing leans heavily on momentum that was generated under the prior CEO. Mason has been permanent CEO since November 2025 and Ryder has been permanent CFO since the same date — both are insiders with strong track records, but the leadership transition has not yet been tested by a missed quarter. Novo Holdings' November 2025 exit at a 5.1% discount also removes a long-standing strategic anchor, even if it eliminates a known overhang.

"It is not always right first time. It has not been as smooth as it could be. Growth last year was good. It was strong, but if we had executed seamlessly, it could have been even stronger." — Jonny Mason, FY25 results, Feb 2026

That is the most candid sentence in any Convatec transcript in five years. It is also the most useful summary of what changes from here.